Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced significant advancements in its oncology programs, including a collaboration with Roche to develop HB-700 for KRAS-mutated cancers. The FDA accepted HOOKIPA's Investigational New Drug Application for HB-300, targeting metastatic castration-resistant prostate cancer. Financially, HOOKIPA reported Q3 2022 revenue of $2.2 million, down from $3.9 million year-over-year, and a net loss of $18.3 million, a decrease from $20.0 million in Q3 2021. HOOKIPA's cash position was robust at $100.7 million as of September 30, 2022.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its Q3 2022 financial results and company update on November 14, 2022, prior to market opening. The company develops immunotherapies based on its proprietary arenavirus platform for serious diseases, including HPV-positive cancers and prostate cancer. Collaborations with Roche and Gilead aim to enhance its immunotherapeutic pipeline. Notably, HOOKIPA will not hold a conference call following this earnings release, indicating a shift in communication strategy with investors.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the Sidoti Micro-Cap Virtual Conference on November 9-10, 2022. The company's corporate presentation is scheduled for November 10 at 12:15 PM EST. The event will be accessible through a webcast on HOOKIPA's website, with an archived replay available for 30 days post-event.
HOOKIPA focuses on developing innovative immunotherapeutics using its proprietary arenavirus platform to combat serious diseases like Human Papillomavirus 16-positive cancers and prostate cancers, with collaborations with Roche and Gilead.
HOOKIPA Pharma has entered a collaboration with Roche to advance its HB-700 program targeting KRAS-mutated cancers, receiving $25 million upfront and potential milestone payments totaling approximately $930 million. This partnership marks HOOKIPA's first oncology licensing collaboration, where they will lead early research and clinical development for HB-700. Roche may expand the collaboration with an additional product candidate, enhancing the commercial potential of HOOKIPA's proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced participation in two major investor conferences: the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, both taking place from September 12-14, 2022 in New York.
The Fireside Chat is scheduled for September 13 at 12:55 PM ET, and can be accessed via HOOKIPA’s website, with archived replays available for 30 days post-event. HOOKIPA focuses on innovative immunotherapies leveraging its proprietary arenavirus platform to tackle diseases, including cancers and viral infections like HBV and HIV.
HOOKIPA Pharma reported promising advancements in its cancer treatments, specifically HB-200 and HB-300. The Phase 1 data for HB-200 in head and neck cancer met all endpoints, leading to a Phase 2 study. Additionally, the FDA accepted the Investigational New Drug Application for HB-300, targeting metastatic castration-resistant prostate cancer. Financially, HOOKIPA's cash position improved significantly, reaching $118.9 million, although revenue fell to $2.7 million from $5.4 million year-over-year, attributed to lower collaboration reimbursements. The net loss decreased slightly to $16.4 million.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its second quarter 2022 financial results and company update on August 11, 2022, prior to market opening. The company, focused on immunotherapies using its proprietary arenavirus platform, aims to mobilize targeted T cells to combat serious diseases. Its pipeline includes investigational therapies for HPV16+ cancers, prostate cancer, KRAS-mutated cancers, and efforts to develop functional cures for HBV and HIV in collaboration with Gilead. No conference call is scheduled for this earnings release.
HOOKIPA Pharma has received FDA acceptance for its IND application for HB-300, a novel immunotherapy targeting metastatic castration-resistant prostate cancer, marking a significant advancement in its oncology pipeline. The Drug Master File (DMF) has also been accepted, facilitating faster clinical development. HB-300 utilizes a dual arenaviral approach to stimulate immune responses against prostate cancer antigens PAP and PSA, with potential expansions to include PSMA. This development is crucial as treatment options are limited for this aggressive cancer form, affecting survival rates.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced key leadership changes effective July 1, 2022, as it advances its clinical development. Igor Matushansky will step down as CMO but will remain as Chair of the Scientific Advisory Board. Katia Schlienger has been promoted to Executive Vice President, Clinical Development, bringing significant experience in oncology therapeutics. Roman Necina becomes Chief Development Officer, integrating project management and operational excellence to enhance pipeline efficiency. The leadership shift aims to strengthen HOOKIPA's capabilities in immunotherapy.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in investor meetings at the JMP Securities Life Sciences Conference on June 15-16, 2022, in New York City. The company focuses on developing immunotherapeutics based on its proprietary arenavirus platform, which aims to enhance T cell responses against serious diseases. HOOKIPA's pipeline includes therapies targeting HPV16+ cancers, prostate cancer, and KRAS-mutated cancers. Additionally, it seeks to develop functional cures for HBV and HIV in collaboration with Gilead.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
